Cargando…
Erythropoietin Receptor Contributes to Melanoma Cell Survival in vivo
Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer. Data from several clinical trials suggest significant adverse effect of Epo treatment on cancer patient survival. However, controversy exists whether erythropoietin receptor (...
Autores principales: | Kumar, Suresh M., Zhang, Gao, Bastian, Boris C., Arcasoy, Murat O., Karande, Pankaj, Pushparajan, Anitha, Acs, Geza, Xu, Xiaowei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441831/ https://www.ncbi.nlm.nih.gov/pubmed/21860424 http://dx.doi.org/10.1038/onc.2011.366 |
Ejemplares similares
-
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
por: Inrig, Jula K, et al.
Publicado: (2011) -
Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and Progression
por: Hardee, Matthew E., et al.
Publicado: (2007) -
Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
por: Khankin, Eliyahu V., et al.
Publicado: (2010) -
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo
por: Christensen, Britt, et al.
Publicado: (2016) -
Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma
por: Ribatti, D, et al.
Publicado: (2007)